AzTrials
AzTrials

Dry EyeNCT07329712

Comparing Tear Proteomics Profile in Dry Eye Disease pre-and Post-treatment With Low Level Light Therapy

An observational study of Dry Eye and Meibomian Gland Dysfunction (Disorder), run by Singapore National Eye Centre at 1 site in Singapore.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record

Search all trials

Trial summary

The purpose of this research study is to understand the mechanism of action of low level light therapy and also potentially yield markers associated with good treatment response. Low-level light therapy is light-based treatment delivered through advance eye-light device. Read more about this study

Who is it for?
Ages 21 years and older
How many people
30 participants
Where
1 siteSingapore
Study dates
5 Nov 2025to 31 Dec 2027
Phase
Observational

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 21 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patient undergoing low level light therapy that met the study inclusion and exclusion

Who may be able to join

  • Must be eligible for, and have consented for low level light therapy
  • Must not have presented to the clinic for an acute eye problem such as visual loss or painful eye
  • Ability to give informed consent.
  • Age more or equals to 21 years old.

Who cannot join

  • Patients who are unable to or decline to give consent.
  • Age less than 21 years old.
  • Patients who presented to the clinic for an acute eye problem such as visual loss or painful eye.
  • Patients not suitable for low level lighttherapy:
  • Pregnant
  • Fitted with pacemakers, metal, electrical, acoustic prosthetics
Show all 12Show fewer
  • Epilepsy, cardiac rhythm or frequency disorders
  • Fever, thrombophlebitis or acute phlebitis of the legs, large-sized varicose veins, or venous surgery within 2 months
  • Uncontrolled hypertension or severe diabetes
  • Open wounds on eyelid or skin
  • Evolving cancer or hepatitis
  • Blood anticoagulant or coagulation defect

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Louis Tong Tong, PhD contact

65767200

louis.tong.h.t@singhealth.com.sg

Jiayi Lee, MSc contact

lee.jiayi1@singhealth.com.sg

Singapore1 site, 1 recruiting
  • Singapore Eye Research Insititute

    Singapore

    Jiayi Lee, MSc, 65767200, lee.jiayi1@singhealth.com.sg

    Recruiting

Other trials in Singapore

About this study

The purpose of this research study is to understand the mechanism of action of low level light therapy and also potentially yield markers associated with good treatment response. Low-level light therapy is light-based treatment delivered through advance eye-light device. This therapy uses light energy to provide energy to the meibomian gland cells to slow down age-ing, improve tear stability and reduce inflammation.

Keywords
Dry Eye, low level light therapy, Eyelight, Tears proteomics, tear cytokine, MGD
Medical subject headings
Dry Eye Syndromes, Meibomian Gland Dysfunction

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07329712
Study groupRoleWhat they receive
Patients undergoing low level light therapyNot described

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Comparing tear proteomics profile in dry eye disease pre-and post-treatment with low level light therapy

    Aim 1: Tear proteomic profile of MGD patients with DED pre- and post-treatment with LLLT will be profiled Aim 2: Baseline tear cytokine levels will be measured using the novel Olink 500-plex technology in DED patients with MGD undergoing LLLT

    Measured: Baseline visit and Post Baseline visit 3 months (+3 weeks).

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Jan 2026
  2. Study start5 Nov 2025
  3. Primary completion31 Dec 2026 (estimated)
  4. Study completion31 Dec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Prospective
Enrolment
30 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07329712
Sponsor's protocol ID
2025-0870
Other IDs
2025-0870
Status last verified
Nov 2025
First submitted
21 Dec 2025
Last updated
9 Jan 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in